{"name":"Epics Therapeutics","slug":"epics-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQSnRPbzI2eURjZnc4ejZmVEVsaExVa21VSWVodG10MUY1dGkwZmFPMHU4eVhzeXlCS01nTDJWT21nR09jZllxcGo1dWx0YXhoVUNlWjUtRTFNekhYeW9rMlZOZGVpTHZXWGVaRTBuWWlLOGc1TDNKNTF2TUNrTzhzVHpLVzR4U1I1OVJUcnNLVW9VclRTRjNBUnEyZm95Y1Q4NGpmSGhPNFdkVnJuaXh4eWJvUFNxTHpGNzFHVUFQc0l4U2d1WFpycXJDVWNiQjlaOEhmSElFVFVqdEpVTTZpSndSUXA4Rkc3VDZRMktERFFOSkNzalpvWWpsMjBWZEZSRE9RRkNn?oc=5","date":"2026-01-06","type":"deal","source":"PR Newswire","summary":"Intune Physical Therapy Acquires Epic Physical Therapy, Expanding Outpatient Physical Therapy Services in North Carolina - PR Newswire","headline":"Intune Physical Therapy Acquires Epic Physical Therapy, Expanding Outpatient Physical Therapy Services in North Carolina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdW9MME5Jb0l0RjRkaEpGdC1MVVJnVTduQjAyTjdHeWFZVGQzRWFEWFFockdMVXpjQjdRb0dRXzZJcGY4V3gxNTFtRW9vRV9CYndGbDVBSGxiOXNpX29XTWg3Z3QxbTNvbHNoUGUxQU52VmFtMzk5QnhzUE9PYzFRczExdzM1cE1VQnJ0TUE2Q3hNQlQ4aWZZMGJ6Z1p0R2h5ZWpfdkplVVlTa2w3ek9UQzNNTXhOa2VRTV9ySWVaTjdTQk0?oc=5","date":"2025-09-01","type":"trial","source":"The Pharma Letter","summary":"Zydus plans filing following positive Phase IIb/III trial of saroglitazar in PPAR - The Pharma Letter","headline":"Zydus plans filing following positive Phase IIb/III trial of saroglitazar in PPAR","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-08-29","type":"trial","source":"Express Pharma","summary":"Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of Saroglitazar in Primary Biliary Cholangitis - Express Pharma","headline":"Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of Saroglitazar in Primary Biliary","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPUktSd2YtRnBaNjZWdHJiLVlGMW1oQmhtVlhBRk5KZ1VySHlXTVlNaFdHYjBsTHFrZFdqMk5pYkgwRFZETmNuRGhtUDNfYVVVd082dS1aQmJXcDJFNkQ4WU1RaG1BWUppY1RiR3FOQmVHZHJLRXJDaXpONXE2c25SZW1teXpuaEV6RW9Xa1o0eGtudjJRcm9GTGFPSVZUSzU0SG9pMUhrUUh3cGRCX0I5N0lyb05DS0YwSUR4ckd3Q19nUFNrTnlhZVZkN3lsZ0R1c2hlSzhGem9VRnczM2dlYTBpeG9wNWkxQnppMWZTdGY1OHJEcWlVUE0wSVdzRGRjd2l2U3hzQXFCQ2FZRTRIbjVqZmROOU5UYk5NYS1oM1FYc2Z2OGliQ2tVVnFRVWpEd3c0?oc=5","date":"2025-08-29","type":"trial","source":"PR Newswire","summary":"Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - PR Newswire","headline":"Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patie","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNTV6S1MtZ1puNmQ2N2dKMXBtWVVqMV9NLTBza2F5R0MzN0VkeXVWWmZFaW5SaEdzY2RPTk80V1d0dGJPSHc2OGtEWS1rdG8xaVhtYXhrZ1hBbXFEYmZRRFpqeUxxVmdZNlNRVzNrSlZpNnVIdzdla2VIeEkzTFpvS3lvMFN0Z0FCdXBBM3ZTM0xFWEp6Z0V2ZDZB?oc=5","date":"2025-08-21","type":"deal","source":"Fierce Biotech","summary":"Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout - Fierce Biotech","headline":"Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFAteDhHdlZ1eU80a2JkRE9ETlp1QzdING9KS1gyWV9wXzVHWmVvaUJhSXRjX21NWHlJSnZVSFpxcXBkd3lxOERiNHdCTWdEakU4QjhSUy1CcjZmRzRtYnhOQldBOGZMTkJjeC1WbmlRdXlfWlhPanZDVA?oc=5","date":"2025-07-31","type":"pipeline","source":"pharmaphorum","summary":"Is AbbVie planning an epic Gilgamesh takeover? - pharmaphorum","headline":"Is AbbVie planning an epic Gilgamesh takeover?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPbmFEdDRmOWhqY29lcHQwTGdPT2hUN3NoLTZ2U2JuTklndHFPajZZZkE3R2dqMnlOTUMycFozZnNLUWhzdEE2VEdheTBHRFBKSE9TRUlWUzdDUkV3cVJKOTk1VFVzY2xXX2VLMUh2ZXJzWmgtTU5jSFNkSVF1dHR2Z1lXV1ZrcF8xSW8ybm9B?oc=5","date":"2025-07-11","type":"pipeline","source":"Life Science Leader","summary":"Epic Bio's Big Swing In Epigenetic Editing - Life Science Leader","headline":"Epic Bio's Big Swing In Epigenetic Editing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQajl5aDVqaXFXYmdlV0ctalIxa3Fac002R2hRbGNLWG5kTkpCcEN1S1VoVV9GTTdCTGk5QUYwZjUyVW9wcDJ3ZEFNRUxZTmw1TDJpbi1FenRTSUttOXNkRkVGSE9NRUVveUlHSTV4S2xvSWRraHFzOTlTM2hUai1DOEU4Qk1wNWFBS0YxRE9LMUZNanZzSU12M2JtelZfR3fSAaQBQVVfeXFMT05zUE92dlFnNWxRY1p0NkswUDhPWldfTnlCbDN1TXlRQUxlUUh2d3lZWlpydElfa2dzcUlWeVk5Y3llQXJEcmV3WlB3Ql9rUUs1Sjk0ekd2bXI5NWxBeVk3VVZDWWN6YmhIOTAwb05yd3I5VUVrVWdibVJmOFZwc3QyUm1Ud0xqMXZpQ1kxcUpaaDMzektEemc2b2F4cjQ3MXZjZG0?oc=5","date":"2025-04-30","type":"pipeline","source":"CNBC","summary":"Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom - CNBC","headline":"Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQRzZXWTg1M2VlVURnNzF3MmVDSzVIWnRfbS1FVFpUZ01Pd3lZNjEza19tS3phVC1NaFExQWF2X3FXVGVLQlVTR25sbnRfbzNCUjJ5dHJLMmdzVnl1Q0RpWTktRldRSmtCaDRibkdMbG1odk01VUZENTJrZmpKc1ZyWGRkOUttQkhDeEdNeWtuVkZRZk9ETDY4dnhEM1E0bHBKYi1Ta0FfV0FRUXNZSEtLaUVWdTlFemhibVBqS1RyZDdyR1k4bVpQcWR1Qml6ZzI0NnVKV2FzdG0xSVJNdk9IVUtQS1c?oc=5","date":"2025-03-27","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients - Genetic Engineering and Biotechnology News","headline":"Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQSWt3S21ZWU1Ca2lzX1NCd0tjMlFQT2dEdTlwQmpWM2FpOU44VmZPbzgwVnRsZUEzcGVLWThld2c1bmNseHpuY1djYTlhUHRKUUpnSUFXXzdvU2JUQjRaWnFmR1I2R1R1NmZ6dm5LMlY2dmFkVHA0RGg4LWJQS20yUmlXaklFZVdELVRBd0ZUeVg0Z2NfZUdkYUltTUdVdlo1?oc=5","date":"2025-03-13","type":"pipeline","source":"massbio.org","summary":"Fixing the IRA: The EPIC Act, MINI Act, and ORPHAN Cures Act - massbio.org","headline":"Fixing the IRA: The EPIC Act, MINI Act, and ORPHAN Cures Act","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFB6OGFaQzM1TXpIOEJWVm5ReUVsLWM1c19EU2t0cUhZdFZfOGVrR3lxcGRMWEVHU25VYUdZelBGd0t1ZzhtdUk3TlNIWE4wdnhXa3ZYMmdndG0wdEhWUnVxRy14aEZWbnAyMmxVZQ?oc=5","date":"2024-08-02","type":"pipeline","source":"Labiotech.eu","summary":"Six epigenetics companies making strides in 2024 - Labiotech.eu","headline":"Six epigenetics companies making strides in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9PalBlU3JDUzdxQ19UVTFPS0VoNTJOWkJBX3hROFMtODBHX1U3M05GWG1NdGVqcHJ3b0JkM3hHb21fYTJHUFVGTnZQS2lBVEFCTWhQcG1Qa04?oc=5","date":"2024-07-18","type":"trial","source":"jnm.snmjournals.org","summary":"Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study - jnm.snmjournals.org","headline":"Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from t","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}